Which Treatment Matches Your Prescription Needs?
Online Prescription Process: Mounjaro and Wegovy Difference Assessment
The online prescription process for both Mounjaro and Wegovy follows identical clinical pathways, though understanding their fundamental differences helps prescribers make personalised recommendations. Wegovy contains semaglutide, a GLP-1 receptor agonist, whilst Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist targeting two hormone pathways simultaneously. Your 3-minute clinical assessment evaluates eligibility for both treatments, covering BMI requirements, medical history, current medications and any contraindications. Licensed UK prescribers registered with our GPhC #9012878 pharmacy review each case individually, considering which mechanism of action aligns with your health profile and treatment goals.
The assessment process removes traditional barriers like GP referrals or specialist appointments, allowing direct access to prescription-only medicines through legitimate clinical channels. Standard prescriber review takes up to 3 working days, with express 24-hour review available for urgent cases. Both Wegovy and Mounjaro require identical eligibility criteria—BMI ≥30 or BMI ≥27 with weight-related comorbidities—but your prescriber considers factors like diabetes history, cardiovascular risk and previous treatment responses when recommending between single or dual hormone therapy. This comprehensive evaluation ensures you receive the most appropriate treatment whilst maintaining full regulatory compliance with MHRA licensing requirements.
Pricing Structure: Mounjaro and Wegovy Difference in Cost Comparison
Wegovy pricing starts at £79.99 for the 0.25mg starter dose after applying our FIRST40 discount code for new customers, with doses escalating to £209.99 for the 2.4mg maintenance strength. Our bundle options provide convenient multi-month supplies, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 or the Ultimate Stability Trio offering three months of 2.4mg maintenance for £649.99. Returning customers benefit from our DOSE25 discount code applied at checkout, with all prices including the full prescription service, prescriber review and next-day temperature-controlled delivery. The structured dose escalation means most patients progress through 4-5 different strengths over 16 weeks before reaching maintenance therapy.
Bundle pricing focuses on convenience rather than savings, ensuring consistent supply without repeated ordering whilst you establish your optimal maintenance dose. The Take-It-Slow bundles accommodate patients requiring extended dose escalation periods, whilst our Consistency bundles provide same-dose supplies for stable maintenance phases. Both treatments require identical clinical monitoring and follow-up assessments, meaning the prescription service costs remain consistent regardless of which medication your prescriber recommends. Payment plans and subscription options ensure affordability for long-term weight management commitments, with transparent pricing eliminating hidden fees or consultation charges beyond the advertised treatment costs.
Clinical Evidence: Mounjaro and Wegovy Difference in Trial Outcomes
Wegovy's clinical evidence stems from the comprehensive STEP trial programme, with STEP 1 demonstrating average weight reductions of approximately 15% at 68 weeks when used alongside reduced-calorie diet and increased physical activity, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, establishing Wegovy's broader health benefits beyond weight management. These results reflect carefully controlled clinical trial conditions and may not represent individual patient outcomes.
Mounjaro's evidence base includes the SURMOUNT trials showing different efficacy patterns, though direct comparison between trial programmes isn't clinically meaningful due to varying study designs, patient populations and endpoints. Both medications demonstrate sustained efficacy when maintained long-term, with STEP 1 extension data indicating patients regained approximately two-thirds of lost weight within one year of discontinuation, emphasising the importance of long-term commitment to treatment.
Mechanism of Action: How Wegovy Works Compared to Mounjaro
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates blood glucose and appetite control through single-pathway activation. This mechanism reduces appetite by acting on brain centres controlling hunger and satiety, whilst slowing gastric emptying to promote feelings of fullness after smaller meals. The once-weekly injection delivers sustained semaglutide levels, maintaining consistent appetite suppression throughout the dosing interval. GLP-1 receptors throughout the digestive system and brain respond to this synthetic hormone, creating multiple pathways for weight management support. Additionally, Wegovy may reduce food cravings and preference for high-calorie foods, though individual responses vary significantly. This single-hormone approach provides targeted appetite control whilst supporting natural metabolic processes when combined with lifestyle modifications.
Prescription Timeline: Ordering Process for Both Treatments
The ordering process begins with our 3-minute online clinical assessment covering medical history, current medications, BMI calculation and treatment goals, with identical questions regardless of which treatment you're considering. Licensed prescribers review submissions within 3 working days (express 24-hour service available), evaluating your suitability for either Wegovy or Mounjaro based on clinical guidelines and individual risk factors. Upon approval, next-day delivery ensures rapid treatment initiation through our temperature-controlled cold-chain logistics, maintaining medication integrity from our GPhC-registered facility to your door. The prescription includes comprehensive dosing instructions, injection technique guidance and safety monitoring requirements for whichever treatment your prescriber recommends. No GP appointment, referral or face-to-face consultation is required, streamlining access to prescription-only medicines whilst maintaining full clinical oversight and regulatory compliance.
Storage Requirements: Mounjaro and Wegovy Difference in Practical Handling
Storage requirements present a significant practical difference between these treatments, with Wegovy offering superior travel and lifestyle flexibility compared to Mounjaro's more restrictive temperature limits. Wegovy FlexTouch pens remain stable for up to 6 weeks at room temperature below 30°C once removed from refrigeration, whilst Mounjaro tolerates only 21 days at room temperature before efficacy may be compromised. Both require refrigerated storage at 2-8°C before first use, but Wegovy's extended room temperature stability suits frequent travellers, shift workers or those with unreliable refrigeration access. The dose escalation schedule requires careful planning for both treatments, with mandatory progression through increasing strengths over 16 weeks before reaching maintenance therapy. Both use pre-filled injection pens with hidden needles, though the specific pen mechanisms and injection techniques differ slightly between manufacturers. This storage advantage often influences treatment selection for patients with demanding work schedules or travel commitments.
Dual vs Single Hormone Action: Mounjaro and Wegovy Difference in Targeting
The fundamental pharmacological difference lies in hormone pathway targeting, with Mounjaro's dual GIP and GLP-1 receptor activation potentially offering broader metabolic effects compared to Wegovy's focused GLP-1 approach. This dual mechanism theoretically provides enhanced glucose regulation and appetite control, though clinical superiority cannot be definitively established without head-to-head comparative trials. Different patients may respond preferentially to single or dual hormone targeting based on their individual metabolic profiles, diabetes status and previous treatment histories.
Your online prescription assessment allows prescribers to evaluate which approach suits your specific circumstances, considering factors like diabetes history, cardiovascular risk and treatment goals. Both mechanisms require identical lifestyle interventions—reduced-calorie diet and increased physical activity—as fundamental components of successful weight management. The choice between single and dual hormone targeting often depends on clinical factors beyond simple efficacy comparison, including side effect profiles, dosing convenience and individual patient preferences discussed during the prescriber review process.
Treatment Selection: Comparing Your Options Through Online Assessment
The online prescription process enables direct comparison of both treatments within a single clinical assessment, with licensed prescribers providing personalised recommendations based on your complete health profile rather than generic treatment preferences. Factors influencing treatment selection include diabetes status, cardiovascular history, previous weight management attempts and lifestyle considerations like travel frequency or injection preferences. Your prescriber considers the storage difference between Wegovy's 6-week room temperature stability versus Mounjaro's 21-day limit when making recommendations for shift workers, frequent travellers or those with demanding schedules. Both Wegovy and Mounjaro are available from EverydayMeds, ensuring you can access either treatment through the same streamlined prescription service without needing separate assessments or prescriber consultations. The decision ultimately rests with your prescriber's clinical judgement, supported by comprehensive assessment data and your individual treatment preferences expressed during the online consultation process.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
